Colorectal Cancer Heterogeneity and Targeted Therapy: A Case for Molecular Disease Subtypes
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Personalized cancer medicine is becoming increasingly important in colorectal cancer treatment. Especially for targeted therapies, large variations between individual treatment responses exist. Predicting therapy response is of utmost significance, as it prevents overtreatment and adverse effects in patients. For EGFR-targeted therapy, many mechanisms of resistance have been uncovered, for example, mutations in KRAS and BRAF, and upregulation of alternative receptors. Currently, routine testing for all known modifiers of response is unpractical, and as a result, decision-making for anti-EGFR therapy is still largely based on assessing the mutation status of an individual gene (KRAS). Recently, comprehensive classifications of colorectal cancer have been presented that integrate many of the (epi-)genetic and microenvironmental factors that contribute to colorectal cancer heterogeneity. These classification systems are not only of prognostic value but also predict therapy efficacy, including the response to anti-EGFR agents. Therefore, molecular subtype–based stratification to guide therapeutic decisions is a promising new strategy that might overcome the shortcomings of single gene testing in colorectal cancer as well as in other malignancies. Furthermore, the development of new agents in a disease subtype–specific fashion has the potential to transform drug-discovery studies and generate novel, more effective therapies. Cancer Res; 75(2); 245–9. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160 · cited 2×
“Vermeulen was supported by a Fellowship of the Dutch Cancer Society (KWF) and an AICR grant (14-1164).”
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 2×
“The role of mutations in KRAS as a selection marker for anti-EGFR therapy has been extensively validated, but it is estimated that only 35%of KRASwild-type tumors do respond to anti-EGFR therapy (1).”
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
kConFab, Lim, E., Vaillant, F., Wu, D., Forrest, N. C., Pal, B., Hart, A. H., Asselin-Labat, M.-L., Gyorki, D. E., Ward, T., et al. (2009) · Nature Medicine · doi:10.1038/nm.2000 · Cited by 1,492 · cited 3×
“Vermeulen was supported by a Fellowship of the Dutch Cancer Society (KWF) and an AICR grant (14-1164).”
De Sousa E Melo, F., Wang, X., Jansen, M., Fessler, E., Trinh, A., de Rooij, L. P. M. H., de Jong, J. H., de Boer, O. J., van Leersum, R., Bijlsma, M. F., et al. (2013) · Nature Medicine · doi:10.1038/nm.3174 · Cited by 771 · cited 4×
“throughout patient-derived xenografting (4).”
InfluentialSelf-citationActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663
Montagut, C., Dalmases, A., Bellosillo, B., Crespo, M., Pairet, S., Iglesias, M., Salido, M., Gallen, M., Marsters, S., Tsai, S. P., et al. (2012) · Nature Medicine · doi:10.1038/nm.2609 · Cited by 513 · cited 2×
“Vermeulen was supported by a Fellowship of the Dutch Cancer Society (KWF) and an AICR grant (14-1164).”
Research works printed but not linked: 24
- De Roock, 2011, KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer, Urol Oncol, 12, 594
- Scartozzi, 2011, Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients, Br J Cancer, 104, 1786, 10.1038/bjc.2011.161 · DOI
- Schlicker, 2012, Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines, BMC Med Genomics, 5, 66, 10.1186/1755-8794-5-66 · DOI · Paper page
- Perez-Villamil, 2012, Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior, BMC Cancer, 12, 260, 10.1186/1471-2407-12-260 · DOI · Paper page
- Budinska, 2013, Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer, J Pathol, 231, 63, 10.1002/path.4212 · DOI · Paper page
- Roepman, 2014, Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition, Int J Cancer, 134, 552, 10.1002/ijc.28387 · DOI · Paper page
- Marisa, 2013, Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value, PLoS Med, 10, e1001453, 10.1371/journal.pmed.1001453 · DOI · Paper page
- Sadanandam, 2013, A colorectal cancer classification system that associates cellular phenotype and responses to therapy, Nat Med, 19, 619, 10.1038/nm.3175 · DOI · Paper page
- Walther, 2009, Genetic prognostic and predictive markers in colorectal cancer, Nat Rev Cancer, 9, 489, 10.1038/nrc2645 · DOI · Paper page
- Malesci, 2007, Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer, Clin Cancer Res, 13, 3831, 10.1158/1078-0432.CCR-07-0366 · DOI · Paper page
- Abulí, 2013, Genetic susceptibility variants associated with colorectal cancer prognosis, Carcinogenesis, 34, 2286, 10.1093/carcin/bgt179 · DOI
- Tosolini, 2011, Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer, Cancer Res, 71, 1263, 10.1158/0008-5472.CAN-10-2907 · DOI · Paper page
- Iida, 2013, Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment, Science, 342, 967, 10.1126/science.1240527 · DOI · Paper page
- Jawad, 2011, Inflammatory bowel disease and colon cancer, Recent Results Cancer Res, 185, 99, 10.1007/978-3-642-03503-6_6 · DOI
- Visvader, 2011, Cells of origin in cancer, Nature, 469, 314, 10.1038/nature09781 · DOI · Paper page
- Takahashi, 2014, Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer, Br J Cancer, 110, 2716, 10.1038/bjc.2014.230 · DOI
- Scartozzi, 2010, Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan, Int J Cancer, 1947, 1941, 10.1002/ijc.25193 · DOI · Paper page
- Wang, 2013, Dissecting cancer heterogeneity–an unsupervised classification approach, Int J Biochem Cell Biol, 45, 2574, 10.1016/j.biocel.2013.08.014 · DOI
- Sadanandam, 2014, Reconciliation of classification systems defining molecular subtypes of colorectal cancer -Interrelationships and clinical implications, Cell Cycle, 13, 353, 10.4161/cc.27769 · DOI · Paper page
- Chen, 2014, Long noncoding RNA profiles identify five distinct molecular subtypes of colorectal cancer with clinical relevance, Mol Oncol, 1
- Nahta, 2006, Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer, Nat Clin Pract Oncol, 3, 269, 10.1038/ncponc0509 · DOI · Paper page
- Ithimakin, 2013, HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab, Cancer Res, 73, 1635, 10.1158/0008-5472.CAN-12-3349 · DOI · Paper page
- Creighton, 2013, Widespread molecular patterns associated with drug sensitivity in breast cancer cell lines, with implications for human tumors, PLoS ONE, 8, e71158, 10.1371/journal.pone.0071158 · doi:10.1371/journal.pone.0071158
- Collisson, 2011, Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy, Nat Med, 17, 500, 10.1038/nm.2344 · DOI · Paper page
Cited by
From tumour heterogeneity to advances in precision treatment of colorectal cancer
Punt, C. J. A., Koopman, M., & Vermeulen, L. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.171 · Cited by 654
Self-citationBiomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
Sveen, A., Bruun, J., Eide, P. W., Eilertsen, I. A., Ramirez, L., Murumägi, A., Arjama, M., Danielsen, S. A., Kryeziu, K., Elez, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1234 · Cited by 256
“Treatment decisions 3 are primarily based on cancer stage and tumor location; however, clinical outcome varies 4 greatly, both with respect to prognosis and treatment response (2).”
BackgroundDeepCC: a novel deep learning-based framework for cancer molecular subtype classification
Gao, F., Wang, W., Tan, M., Zhu, L., Zhang, Y., Fessler, E., Vermeulen, L., & Wang, X. (2019) · Oncogenesis · doi:10.1038/s41389-019-0157-8 · Cited by 226
Self-citationImpact of the spheroid model complexity on drug response
Hoffmann, O. I., Ilmberger, C., Magosch, S., Joka, M., Jauch, K.-W., & Mayer, B. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.02.029 · Cited by 125
Metadata
- Authors
- Linnekamp, J. F., Wang, X., Medema, J. P., & Vermeulen, L.
- Venue
- Cancer Research
- Published
- 2015-01-14
- Volume
- 75
- Issue
- 2
- Pages
- 245-249
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2058145479
- Cited by
- 202
- References
- 13
- FWCI
- 10.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Colorectal Cancer Heterogeneity and Targeted Therapy: A Case for Molecular Disease Subtypes. https://app.cochat.ai/papers/10.1158/0008-5472.can-14-2240
- The paper
- Linnekamp, J. F., Wang, X., Medema, J. P., & Vermeulen, L. (2015). Colorectal Cancer Heterogeneity and Targeted Therapy: A Case for Molecular Disease Subtypes. Cancer Research. https://doi.org/10.1158/0008-5472.can-14-2240
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.